Establishment Labs Holdings Inc.
ESTA Healthcare Medical Devices
Establishment Labs Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $211.1 million, up 27.1% from fiscal 2024.
- Revenue
- +31.7%
- EPS
- +31.6%
- Free cash flow
- +2.75%
- Total debt
- +18.3%
Quarter to June 2026, against a year earlier
Follow ESTA
Alert me
Establishment Labs Holdings Inc. (ESTA) P/E ratio
Establishment Labs Holdings Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 34 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BFLY Butterfly Network, Inc. compare | n/m |
| ESTA Establishment Labs Holdings Inc. | n/m |
| NEOG Neogen Corporation compare | n/m |
| NVCR NovoCure Limited compare | n/m |
| ALMR Alamar Biosciences, Inc. compare | n/m |
| TMDX TransMedics Group, Inc. compare | 16.4× |
| INSP Inspire Medical Systems, Inc. compare | 19.1× |
| CNMD CONMED Corporation compare | 21.7× |
| UFPT UFP Technologies, Inc. compare | 30.1× |
| Medical Devices industry median | 25.6× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)